Despite scarce data on CV protection for mineralocorticoid receptor antagonists (MRAs), 11% of responders considered them as the first-line option for hypertensive CS patients, probably to target the pseudo-hyperaldosteronism secondary to cortisol excess [22]. This evidence concerns the gene NR3C2 and hyperaldosteronism.